ClinicalTrials.gg
Not yet recruitingNCT06578286Updated Aug 29, 2024

ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd

A Phase 2 interventional study of ARX788 in Breast Cancer, sponsored by Fudan University. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-29.

Sponsored by Fudan University · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing ARX788 in Breast Neoplasms — 3 open to participants now, 5 under way, 1 of them phase 3. ARX788 · Breast Neoplasms.

Planned enrollment
6th of 10
44 · median 49
Started
2024
the only one that year
Phase 2
7 of 10
3 open now
Registered
9th of 10
by date
Lead sponsor
3 of 10
Fudan University

Among the 10 studies testing ARX788 in Breast Neoplasms, this one is the 6th largest by planned enrollment, is the only one that started in 2024, is one of 7 in phase 2, and was the 9th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

3 of the 10 studies testing ARX788 in Breast Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ARX788

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing ARX788 in Breast Neoplasms, or all of them as a file.
02

Study summary

A single arm, phase 2 Study of ARX788 in HER2-positive metastatic breast cancer patients who were previously treated with T-DXd. The ARX788 will be administered every 3 weeks (Q3W) intravenous (IV) infusion.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 to 75 years old (including upper and lower limits), male or female;
  2. Unresectable locally advanced, recurrent or BC;
  3. Tissue samples determined to be positive (defined as IHC3+ or FISH+);
  4. Received T-DXd treatment in the advanced stage;
  5. Adequate bone marrow, liver, kidney and coagulation function;
  6. Voluntarily sign the , have good compliance and are willing to comply with the follow-up visit.

Exclusion criteria

Exclusion Criteria:

  1. With meningeal or disseminated or active brain metastases;
  2. Has interstitial lung disease requiring therapy, a history of drug-induced interstitial lung disease, a history of radiation pneumonitis, or any evidence indicating clinically active interstitial lung disease;
  3. Has any eye disease that require medical intervention such as keratitis, corneal diseases or active eye infection;
  4. Has cardiac insufficiency;
  5. Has received any systemic anti-tumor therapy (with the exception of endocrine therapy, with an interval of at least 7 days) within 28 days (or at least 5 half-lives) before the first use of the product;
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    ARX788

    ARX788,1.5 mg/kg IV infusion on Day 1 of each 21-day treatment cycle

    Drug: ARX788

Interventions

  • DrugARX788

    ARX788,1.5 mg/kg IV infusion on Day 1 of each 21-day treatment cycle

06

What researchers measure

Primary outcomes

  1. Objective remission rate (ORR)

    The proportion of patients who have a CR or PR, as determined by the Investigator at local site per RECIST 1.1.

    Time frame: Until progression, assessed up to approximately 24 months

Secondary outcomes

  1. Disease control rate (DCR)

    The proportion of patients who have a CR or PR or SD, as determined by the Investigator at local site per RECIST 1.1.

    Time frame: Baseline through end of study, assessed up to 24 months]

  2. Duration of relief (DOR)

    Time from the date of first documented response until the date of documented progression or death in the absence of disease progression

    Time frame: Until progression, assessed up to approximately 24 months

  3. Progression-free survival (PFS)

    Time to progression as assessed by the Investigator at local site per RECIST 1.1, or death due to any cause.

    Time frame: Until progression or death, assessed up to approximately 36 months]

  4. Overall survival (OS)

    Time to death due to any cause

    Time frame: Until death, assessed up to approximately 50 months

  5. The number of subjects experiencing adverse event TEAEs

    Occurrence of AEs according to CTCAE v5.0

    Time frame: Up to follow-up period, approximately 50 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2024; primary completion for Sep 2026, 24 months later.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 24 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2024
First posted
Aug 29, 2024
StartEst.
Sep 30, 2024
Primary completionEst.
Sep 30, 2026
CompletionEst.
Sep 30, 2030
Last update
Aug 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06578286
Lead sponsor
Fudan University
Responsible party
Jian Zhang,MD (Chief Physician, Fudan University) — Principal investigator
First posted
Aug 29, 2024
Start date
Sep 30, 2024 (estimated)
Primary completion
Sep 30, 2026 (estimated)
Completion
Sep 30, 2030 (estimated)
Last update
Aug 29, 2024

Study contacts

Jian Zhang, MD,PhD
Contact
syner2000@163.com
+8664175590 ext. 85000
Yanchun Meng, MD
Contact
ycmnankai@126.com
+8664175590 ext. 85000

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ARX788

Start the discussion